AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections

/in

RICHMOND, Va. & LJUBLJANA, Slovenia, & SYDNEY — March 31, 2015. Link here. Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, March 31, 2015 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has granted European patent no. EP […]

Read more

Avita Announces $A5M Placement and Initiates Share Purchase Plan

/in

Northridge, CA and Cambridge, UK, 11 March 2015 – Link here. Avita Medical Ltd (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a placement to sophisticated and institutional investors and launched a Share Purchase Plan (“SPP”). The placement raised $A5,042,280.00 through the issuance […]

Read more

FierceBiotech – Intrexon partner AmpliPhi raises $13M for antibiotic R&D

/in

March 11, 2015 | By Damian Garde – Link here. AmpliPhi BioSciences has lined up $13 million in private placement cash, selling stock and warrants to fund its pipeline of treatments for drug-resistant bacterial infections. The Richmond, VA, biotech is issuing nearly 79 million shares at $0.165 apiece to a group of investors including partner Intrexon ($XON), […]

Read more

AmpliPhi BioSciences Corporation Announces $13 Million Financing

/in

March 10, 2015 05:07 PM Eastern Daylight Time. Link here. RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY–(BUSINESS WIRE)–AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, […]

Read more